6-氨基异喹啉 | 23687-26-5

• 物质功能分类: 医药中间体 - 异喹啉类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 中文名称: 6-氨基异喹啉
• 中文别名: 6-异喹啉胺
• 英文名称: 6-isoquinolinamine
• 英文别名: 6-amino-isoquinoline；isoquinolin-6-amine；6-Aminoisochinolin；isoquinoline-6-amine；6-Aminoisoquinoline
• CAS: 23687-26-5
• 化学式: C₉H₈N₂
• mdl: MFCD04114862
• 分子量: 144.176
• InChiKey: NGFCTYXFMDWFRQ-UHFFFAOYSA-N

物化性质

• 熔点：
  211-212 °C(Solv: benzene (71-43-2))
• 沸点：
  343.1±15.0 °C(Predicted)
• 密度：
  1.210±0.06 g/cm3(Predicted)
• 溶解度：
  DMF（少量溶解）、DMSO（少量溶解）、甲醇（少量溶解）

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险品标志：
  Xn
• 安全说明：
  S26
• 危险类别码：
  R22,R36
• 海关编码：
  2933499090
• 危险性防范说明：
  P305+P351+P338
• 危险性描述：
  H302,H319
• 储存条件：
  室温

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 6-Aminoisoquinoline
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H302: Harmful if swallowed
H319: Causes serious eye irritation
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing

---

Section 3. Composition/information on ingredients.
Ingredient name: 6-Aminoisoquinoline
CAS number: 23687-26-5

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
Eye contact:
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels, refrigerated.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C9H8N2
Molecular weight: 144.2

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

6-氨基异喹啉是一种氮杂环化合物，具有良好的药用和医用价值。许多药物都是基于氮杂环化合物的衍生物。作为重要的一类氮杂环化合物，6-氨基异喹啉不仅是多环氮杂芳烃化合物合成中的关键中间体，还展现出潜在的抗癌活性。

制备

在100毫升三口瓶中加入500毫升水、60克铁屑及少量盐酸，并加热至95℃。随后加入76克6-硝基异喹啉和3克催化剂，在95℃下保温一段时间。当取一滴反应液滴到滤纸上，黄色渗圈消失时即为反应终点。接着加入NaOH溶液进行中和，过滤后将滤液加盐酸酸析，再次过滤即可得到目标产物6-氨基异喹啉。

反应信息

• 作为反应物：
  描述：

  6-氨基异喹啉 在 盐酸 、 sodium nitrite 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 1.5h， 生成
  参考文献：
  名称：

  NOVEL SUBSTITUTED ISOQUINOLINE DERIVATIVE

  摘要：

  本发明提供了一种新型的异喹啉-6-磺酰胺衍生物，该衍生物可用作药物。本发明提供了一种由公式（1）表示的异喹啉-6-磺酰胺衍生物，其盐，或衍生物或盐的溶剂化物，其中R1和R2各自独立地代表氢原子或类似物；R3和R4各自独立地代表氢原子、烷基或类似物；R5代表氢原子、可选地取代的烷基、可选地取代的烯基、可选地取代的炔基、可选地取代的环烷基、可选地取代的烷酰基或类似物；A代表具有2至6个碳原子的直链或支链亚烷基。

  公开号：

  US20130274269A1
• 作为产物：
  描述：

  6-溴异喹啉 在 ammonium hydroxide 、 copper(ll) sulfate pentahydrate 作用下， 以 水 为溶剂， 反应 6.0h， 以85%的产率得到6-氨基异喹啉
  参考文献：
  名称：

  SUBSTITUTED ISOQUINOLINE DERIVATIVE

  摘要：

  本发明提供了一种作为新型药物剂的异喹啉-6-磺酰胺衍生物。本发明提供了由式（1）表示的异喹啉-6-磺酰胺衍生物，其盐或该衍生物或盐的溶剂：其中X和Y分别独立表示直接键，NH，CH═CH，O或S；R1和R2分别独立表示氢原子，卤素原子，氰基，烷基或类似物；R3和R4分别独立表示氢原子，烷基或类似物，或R3和R4共同形成烷基或烯基，可以在两个碳原子之间被桥接到任意位置；l，m和n表示1到4的整数。

  公开号：

  US20120035159A1
• 作为试剂：
  描述：

  6-氨基异喹啉 、 methyl 3-(1,3-dioxoisoindolin-2-yl)-2-(4-(((triisopropylsilyl)oxy)methyl)phenyl)propanoate 在 6-氨基异喹啉 作用下， 生成 3-(1,3-dioxoisoindolin-2-yl)-N-(isoquinolin-6-yl)-2-(4-((triisopropylsilyloxy)methyl)phenyl)propanamide
  参考文献：
  名称：

  Dual mechanism inhibitors for the treatment of disease

  摘要：

  提供了同时抑制rho激酶和单胺转运体（MAT）的化合物，用于改善疾病状态或病情。此外还提供了包含这些化合物的组合物。进一步提供了使用该发明的化合物治疗疾病或病情的方法。其中一种疾病可能是青光眼，除了其他有益的效果外，还可以显著降低眼内压（IOP）。

  公开号：

  US10316029B2

文献信息

• Structure–Activity Relationship for Small Molecule Inhibitors of Nicotinamide<i>N</i>-Methyltransferase
  作者：Harshini Neelakantan、Hua-Yu Wang、Virginia Vance、Jonathan D. Hommel、Stanton F. McHardy、Stanley J. Watowich

  DOI：10.1021/acs.jmedchem.7b00389

  日期：2017.6.22

  biotransforming enzyme that catalyzes the N-methylation of endogenous and exogenous xenobiotics. We have identified small molecule inhibitors of NNMT with >1000-fold range of activity and developed comprehensive structure–activity relationships (SARs) for NNMT inhibitors. Screening of N-methylated quinolinium, isoquinolinium, pyrididium, and benzimidazolium/benzothiazolium analogues resulted in the

  烟酰胺N-甲基转移酶（NNMT）是一种基本的胞质生物转化酶，可催化内源性和外源性异源生物的N-甲基化。我们已经确定了具有> 1000倍活性范围的NNMT小分子抑制剂，并为NNMT抑制剂开发了全面的结构-活性关系（SAR）。筛选N-甲基化的喹啉鎓，异喹啉鎓，吡啶鎓和苯并咪唑鎓/苯并噻唑鎓类似物导致鉴定出喹啉鎓是极有希望的具有极低摩尔浓度的支架（IC 50〜1μM）NNMT抑制。基于抑制剂的计算机对接至NNMT底物（烟酰胺）的结合位点在配体-酶相互作用对接得分与实验计算的IC 50值之间产生了稳固的相关性。预测的喹啉类似物的结合方向揭示了与NNMT底物结合位点残基的选择性结合以及驱动蛋白质-配体分子间相互作用和NNMT抑制的基本化学特征。这一新系列的小分子NNMT抑制剂的开发指导了类药物前体抑制剂的未来设计，以治疗以NNMT活性异常为特征的几种代谢和慢性疾病。
• [EN] PYRIMIDINE DERIVATIVES CAPABLE OF INHIBITING ONE OR MORE KINASES<br/>[FR] DÉRIVÉS DE PYRIMIDINE CAPABLES D'INHIBER UNE OU PLUSIEURS KINASES
  申请人：MEDICAL RES COUNCIL

  公开号：WO2009122180A1

  公开（公告）日：2009-10-08

  A first aspect of the invention relates to a compound of formula (I), or a pharmaceutically acceptable salt or ester thereof, formula (I): wherein: R1 is C3-8-cycloalkyl; X is O, NR7 or C3-6-heterocycloalkyl; R2 is aryl, heteroaryl, fused or unfused aryl-C3-6-heterocycloalkyl or fused or unfused heteroaryl-C3-6-heterocycIoalkyl, each of which is optionally substituted by one or more substitutents selected from aryl, heteroaryl, C1-6-alkyl, C3-7-cycloalkyl and a group A, wherein said C1-6-alkyl group is optionally substituted by one or more substituents selected from aryl, heteroaryl, R10 and a group A, said heteroaryl group is optionally substituted by one or more R10 groups; and wherein said C3-6-heterocycloalkyl group optionally contains one or more groups selected from oxygen, sulfur, nitrogen and CO; R3 is C1-6-alkyl optionally substituted by one or more substituents selected from aryl, heteroaryl, -NR4R5, -OR6, -NR7(CO)R6, -NR7(CO)NR4R5, -NR7SO2R6, -NR7COOR7, -CONR4R5, C3-6-heterocycloalkyl and formula (a, b, c): wherein R4-7 and A are as defined in the claims. Further aspects relate to the use of said compounds in the treatment of various therapeutic disorders, and more particularly as inhibitors of one or more kinases.

  本发明的第一个方面涉及式(I)的化合物，或其药学上可接受的盐或酯，式(I)如下：其中：R1为C3-8环烷基；X为O、NR7或C3-6杂环烷基；R2为芳基、杂芳基、融合或未融合的芳基-C3-6杂环烷基或融合或未融合的杂芳基-C3-6杂环烷基，每个基可选择地由来自芳基、杂芳基、C1-6烷基、C3-7环烷基和A基的一个或多个取代基取代，其中所述C1-6烷基基可选择地由来自芳基、杂芳基、R10和A基的一个或多个取代基取代，所述杂芳基可选择地由一个或多个R10基取代；以及所述C3-6杂环烷基基可选择地包含一个或多个来自氧、硫、氮和CO的基；R3为C1-6烷基，可选择地由一个或多个来自芳基、杂芳基、-NR4R5、-OR6、-NR7(CO)R6、-NR7(CO)NR4R5、-NR7SO2R6、-NR7COOR7、-CONR4R5、C3-6杂环烷基和式(a, b, c)的取代基取代；其中R4-7和A如权利要求中所定义。进一步方面涉及所述化合物在治疗各种治疗性疾病中的使用，特别是作为一个或多个激酶的抑制剂。
• [EN] BORON-CONTAINING RHO KINASE INHIBITORS<br/>[FR] INHIBITEURS DE LA RHO KINASE CONTENANT DU BORE
  申请人：PERCIPIAD INC

  公开号：WO2021011873A1

  公开（公告）日：2021-01-21

  The present invention provides boron-containing isoquinoline compounds as protein kinase-modulating compounds. These compounds are useful as neuroprotective and neuro-regenerative agents for the amelioration of glaucoma and other ocular neuropathies.

  本发明提供了含硼的异喹啉化合物作为蛋白激酶调节化合物。这些化合物可用作神经保护和神经再生剂，用于改善青光眼和其他眼神经病变。
• Heterocyclic compounds as inhibitors of factor VIIa
  申请人：Glunz W. Peter

  公开号：US20060211720A1

  公开（公告）日：2006-09-21

  The present invention relates generally to compounds that inhibit serine proteases. In particular it is directed to novel heterocyclic compounds, or a stereoisomer or pharmaceutically acceptable salt, solvate, or prodrug form thereof, which are useful as selective inhibitors of serine protease enzymes of the coagulation cascade; for example thrombin, factor VIIa, factor Xa, factor XIa, factor IXa, and/or plasma kallikrein. In particular, it relates to compounds that are factor VIIa inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of using the same.

  本发明一般涉及抑制丝氨酸蛋白酶的化合物。具体而言，它涉及新颖的杂环化合物，或其立体异构体或药用可接受的盐、溶剂合物或前药形式，这些化合物可用作凝血级联中丝氨酸蛋白酶的选择性抑制剂；例如凝血酶、第VIIa因子、第Xa因子、第XIa因子、第IXa因子和/或血浆激肽。具体而言，它涉及第VIIa因子抑制剂的化合物。本发明还涉及包含这些化合物的药物组合物以及使用它们的方法。
• Highly Chemo‐ and Regioselective Reduction of Aromatic Nitro Compounds Catalyzed by Recyclable Copper(II) as well as Cobalt(II) Phthalocyanines
  作者：Upendra Sharma、Praveen Kumar、Neeraj Kumar、Vishal Kumar、Bikram Singh

  DOI：10.1002/adsc.201000191

  日期：2010.10.9

  Copper/cobalt phthalocyanines were established for the first time as catalysts for the very efficient chemo- and regioselective reduction of aromatic nitro compounds to generate the corresponding amines. The selective reduction of nitro compounds was observed in the presence of a large range of functional groups such as aldehyde, keto, acid, amide, ester, halogen, lactone, nitrile and heterocyclic

  铜/钴酞菁是首次建立的，用于非常有效地化学和区域选择性还原芳香族硝基化合物以生成相应的胺的催化剂。在存在大量官能团如醛，酮，酸，酰胺，酯，卤素，内酯，腈和杂环官能团的情况下，观察到硝基化合物的选择性还原。此外，发现本方法对在短时间内以高收率还原芳族二硝基化合物具有高度区域选择性。在大多数情况下，通过GC-MS监测，转化率和选择性均> 99％。通过紫外可见光谱和电喷雾电离四极杆飞行时间串联质谱分析了还原机理。